Milestone Pharmaceuticals (NASDAQ:MIST) CEO Sells $82,490.00 in Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 36,500 shares of the stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the sale, the chief executive officer directly owned 446,244 shares in the company, valued at $1,008,511.44. This trade represents a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joseph Oliveto also recently made the following trade(s):

• On Monday, January 26th, Joseph Oliveto sold 34,523 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total value of $66,629.39.

Milestone Pharmaceuticals Trading Up 4.7%

Milestone Pharmaceuticals stock opened at $2.01 on Thursday. The company has a debt-to-equity ratio of 1.37, a current ratio of 8.01 and a quick ratio of 7.96. Milestone Pharmaceuticals Inc. has a one year low of $1.00 and a one year high of $3.06. The stock has a market capitalization of $236.52 million, a PE ratio of -2.54 and a beta of 0.69. The business’s fifty day moving average is $1.66 and its 200 day moving average is $1.94.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Friday, March 20th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business had revenue of $1.44 million for the quarter, compared to analysts’ expectations of $37.52 million. On average, sell-side analysts predict that Milestone Pharmaceuticals Inc. will post -0.64 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Creative Planning boosted its position in Milestone Pharmaceuticals by 74.6% in the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after purchasing an additional 10,000 shares during the last quarter. Raymond James Financial Inc. boosted its position in Milestone Pharmaceuticals by 30.1% in the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after purchasing an additional 10,000 shares during the last quarter. Bay Rivers Group boosted its position in Milestone Pharmaceuticals by 72.9% in the fourth quarter. Bay Rivers Group now owns 28,861 shares of the company’s stock worth $58,000 after purchasing an additional 12,170 shares during the last quarter. Sapient Capital LLC purchased a new position in Milestone Pharmaceuticals in the third quarter worth about $25,000. Finally, Strategic Family Wealth Counselors L.L.C. bought a new position in shares of Milestone Pharmaceuticals in the fourth quarter worth about $25,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on MIST shares. Raymond James Financial started coverage on Milestone Pharmaceuticals in a research report on Friday, April 10th. They set a “strong-buy” rating and a $6.00 price objective on the stock. Zacks Research cut Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 24th. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research report on Monday, December 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.